Holen Sie sich die Stockscreener-App
10.25
0.49%
0.05
Schlusskurs vom Vortag:
$10.20
Offen:
$10.2
24-Stunden-Volumen:
60,915
Relative Volume:
0.85
Marktkapitalisierung:
$299.91M
Einnahmen:
$65.42M
Nettoeinkommen (Verlust:
$-32.96M
KGV:
-6.0294
EPS:
-1.7
Netto-Cashflow:
$-19.87M
1W Leistung:
+11.53%
1M Leistung:
+61.42%
6M Leistung:
+36.12%
1J Leistung:
+15.69%
1-Tages-Spanne:
$9.79
$10.46
1-Wochen-Bereich:
$8.76
$10.77
52-Wochen-Spanne:
$5.45
$18.15
Neuropace Inc Stock (NPCE) Company Profile
Firmenname
Neuropace Inc
Sektor
Branche
Telefon
(650) 237-2700
Adresse
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Vergleichen Sie NPCE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
10.25 | 299.91M | 65.42M | -32.96M | -19.87M | -1.70 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-14 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Eingeleitet | Lake Street | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-05-17 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
NeuroPace's SWOT analysis: epilepsy device maker's stock poised for growth - Investing.com
NeuroPace, Inc. (NASDAQ:NPCE) Receives $14.60 Average PT from Analysts - MarketBeat
NeuroPace, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Top 10 Deep Brain Stimulation Device Companies | Provides Best DevicesMarket.us Media - Market.us Media - United States Market News
NeuroPace (NASDAQ:NPCE) versus Cerus (NASDAQ:CERS) Financial Analysis - Defense World
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates - MSN
What Makes NeuroPace (NPCE) a New Buy Stock - MSN
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 54.34%: Here's is How to Trade - Yahoo Finance
NeuroPace FY2024 EPS Forecast Raised by Cantor Fitzgerald - Defense World
Cantor Fitzgerald Boosts Earnings Estimates for NeuroPace - MarketBeat
NeuroPace (NASDAQ:NPCE) Price Target Cut to $13.00 by Analysts at Wells Fargo & Company - Defense World
FY2024 EPS Estimates for NeuroPace Lifted by Leerink Partnrs - Defense World
NeuroPace FY2024 EPS Forecast Boosted by Leerink Partnrs - MarketBeat
NeuroPace Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Here's What Analysts Are Forecasting For NeuroPace, Inc. (NASDAQ:NPCE) After Its Third-Quarter Results - Simply Wall St
Long NPCE: NeuroPace Inc. Q3 Earnings, 28% Revenue Growth, Nautilus Study Progress, and Breakout from $6-$7 Consolidation Signal Bullish Momentum - Invezz
How the (NPCE) price action is used to our Advantage - Stock Traders Daily
NeuroPace price target lowered to $13 from $15 at Wells Fargo - TipRanks
NeuroPace, Inc. (NASDAQ:NPCE) Q3 2024 Earnings Call Transcript - Insider Monkey
500: Something went wrong - Investing.com Canada
NeuroPace Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance - The Manila Times
NeuroPace, Inc. Reports Strong Q3 2024 Results - TipRanks
NeuroPace Inc.: Q3 Earnings Snapshot - San Francisco Chronicle
Neuropace earnings beat by $0.08, revenue topped estimates - Investing.com UK
Neuroscience Market Projected to Reach USD 50.2 Billion by 2032, Growing at a 4.0% CAGR – S&S Insider - GlobeNewswire Inc.
Earnings To Watch: NeuroPace Inc (NPCE) Reports Q3 2024 Result - Yahoo Finance
NeuroPace (NPCE) Set to Announce Earnings on Tuesday - Defense World
private equity firms who own 45% along with institutions invested in NeuroPace, Inc. (NASDAQ:NPCE) saw increase in their holdings value last week - Yahoo Finance
Does NeuroPace (NASDAQ:NPCE) Have A Healthy Balance Sheet? - Simply Wall St
NeuroPace submits RNS System study data to FDA By Investing.com - Investing.com Australia
NeuroPace (NPCE) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy - ForexTV.com
NeuroPace submits RNS System study data to FDA - Investing.com India
How to Take Advantage of moves in (NPCE) - Stock Traders Daily
Analysts Set NeuroPace, Inc. (NASDAQ:NPCE) Target Price at $14.00 - Defense World
NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Strength Seen in NeuroPace (NPCE): Can Its 5.1% Jump Turn into More Strength? - MSN
Deep Brain Stimulation Devices Market Growing Popularity & Emerging Trends | Medtronic, NeuroPace, LivaNova - openPR
KCK LTD.'s Strategic Reduction in NeuroPace Inc Shares - Yahoo Finance
Neuropace shareholder KCK Ltd. sells $1.22 million in stock By Investing.com - Investing.com South Africa
Neuropace shareholder KCK Ltd. sells $1.22 million in stock - Investing.com
Ltd. Kck Sells 223,991 Shares of NeuroPace, Inc. (NASDAQ:NPCE) Stock - MarketBeat
KCK LTD. Adjusts Stake in NeuroPace Inc - GuruFocus.com
Neuropace Inc sees $24,853 stock sale by major shareholder - Investing.com
Page 85 – Impact Investing - Equities News
Neuropace stock hits 52-week low at $5.66 amid market challenges - Investing.com Australia
Finanzdaten der Neuropace Inc-Aktie (NPCE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neuropace Inc-Aktie (NPCE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KCK LTD. | 10% Owner |
Oct 23 '24 |
Sale |
6.02 |
147 |
885 |
5,494,836 |
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):